Skip to Main Content

Paper Details

Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.
Crit Care Med
16
2022
Author NameAffiliation
Shashi BellamNorthShore University HealthSystem
David N HagerJohns Hopkins University
  • 1 - 2

Datasets

Release 1.2